No longevity supplement category has generated more hype — or more consumer spending — than NMN NAD precursors. The premise is simple and seductive: NAD+, a coenzyme essential for cellular energy metabolism and sirtuin activity, declines with age; therefore, supplementing with precursors that raise NAD+ should restore youthful function. The reality, once you read the human trials carefully, is messier and more interesting. This is an honest 2026 evidence review.
What Are NAD+ Precursors?
Nicotinamide adenine dinucleotide (NAD+) is one of the most fundamental molecules in biology, discovered in 1906 by Harden and Young and later recognized as a critical coenzyme by Otto Warburg. It shuttles electrons in cellular respiration, serves as a substrate for sirtuins (the longevity-associated deacetylase family), and is consumed by PARPs during DNA repair and by CD38 during inflammation. Tissue NAD+ levels decline meaningfully with age — a finding reported across multiple model organisms and human tissues — which is the central motivator for "NAD+ restoration" as an aging intervention.
Several precursors can raise intracellular NAD+ via the salvage pathway:
- Nicotinic acid (NA / niacin) — the original vitamin B3, associated with flushing at high doses
- Nicotinamide (NAM) — another B3 form, minimal flushing, but can inhibit sirtuins at high concentrations
- Nicotinamide riboside (NR) — commercialized by ChromaDex as Niagen, the most extensively studied precursor in humans
- Nicotinamide mononucleotide (NMN) — popularized in part by David Sinclair, one step closer to NAD+ in the salvage pathway
- NAD+ itself (IV, topical, nasal) — controversial, with questionable cellular uptake
The NMN-versus-NR debate, and the ChromaDex-versus-Elysium litigation that accompanied it, are a useful reminder that much of this field has operated as both science and commerce simultaneously.
How They Work
The salvage pathway of NAD+ biosynthesis converts dietary and recycled precursors into NAD+ through a handful of enzymatic steps. NR is phosphorylated by NRK1/2 to NMN, and NMN is adenylated by NMNATs to NAD+. In vitro and in rodent studies, oral NR and NMN both raise tissue NAD+ levels. The mechanistic hope is that restored NAD+ will:
- Reactivate sirtuins (SIRT1, SIRT3, SIRT6), improving metabolic and stress-response signaling
- Support PARP-mediated DNA repair
- Improve mitochondrial function and oxidative phosphorylation capacity
- Reduce senescence-associated secretory phenotype inflammation
There is also real biology here. The complicated question is whether oral precursors at realistic doses meaningfully restore functional NAD+ in the tissues that matter in humans, and whether that restoration translates to outcomes people care about.
The Evidence
Do NAD+ precursors actually raise NAD+ in humans?
Yes, modestly, and mostly in blood. Key trials:
- Trammell, Schmidt, Weidemann et al. 2016 (Nature Communications): the first published human NR pharmacokinetic study. Oral NR raised blood NAD+ dose-dependently and was well tolerated.
- Martens, Denman, Mazzo et al. 2018 (Nature Communications): a placebo-controlled trial in middle-aged and older adults showed NR raised whole-blood NAD+ by roughly 60% and produced a modest reduction in systolic blood pressure in a subgroup with elevated baseline BP. No change in insulin sensitivity, lipid profile, or most metabolic endpoints.
- Yoshino, Baur, Imai 2018 review and Yoshino et al. 2021 (Science): a small human NMN trial in postmenopausal prediabetic women showed improved muscle insulin sensitivity and remodeling markers. Positive, but small and needing replication.
- Irie, Okamoto, Uchida et al. 2020 (Endocrine Journal): a small single-dose NMN safety and pharmacokinetic study in men, showing acceptable tolerability up to 500 mg.
- Dollerup et al. 2020 and follow-ups: multiple NR trials in obese men and older adults have shown clean raises in NAD+ without convincing improvements in insulin sensitivity, muscle function, or metabolic health endpoints.
The honest summary: oral NR and NMN do raise blood NAD+, but the functional downstream effects in humans have been mixed, modest, and frequently null on primary endpoints.
What we don't have
- No human lifespan data — not even close
- No mortality data
- No convincing cognitive improvement data in well-controlled trials
- Limited tissue-level NAD+ data outside of blood (muscle biopsies in some studies show some changes)
The commercial and regulatory backdrop
ChromaDex (NR / Niagen) and Elysium Health fought extended patent and contract litigation that shaped how NR was marketed in the late 2010s. NMN had its own regulatory drama: in 2022, the FDA effectively ruled that NMN could not be sold as a dietary supplement because it was being investigated as a drug. The ruling was initially disruptive, and enforcement has been uneven; NMN remained available through many channels, and the regulatory status stays unsettled in 2026.
What Researchers and Clinicians Are Doing Today
David Sinclair (Harvard) remains the most publicly associated researcher with NAD+ precursors, though he has emphasized NMN more than NR and has consistently been careful to distinguish mechanism from outcome claims in peer-reviewed settings. Other major voices — Charles Brenner, who discovered NR as a NAD+ precursor, and Joseph Baur at Penn — have publicly critiqued overclaiming on NMN's benefits and have pushed for rigorous human trial data.
In clinical practice, functional medicine and longevity clinics often prescribe 300–1000 mg/day of NR or NMN, sometimes alongside resveratrol, pterostilbene, or TMG (to counter potential methylation burden from nicotinamide metabolism). Intravenous NAD+ infusions remain popular in concierge clinics despite limited evidence that IV NAD+ meaningfully enters cells versus being metabolized at the membrane.
Connection to Gene Editing and Peptides
NAD+ biology intersects with multiple areas of longevity science. Sirtuins — the headline NAD+-dependent enzymes — are implicated in epigenetic age regulation and interact with chromatin modifications that partial reprogramming strategies also target. NAD+ is directly required for PARP-mediated DNA repair, which is relevant to CRISPR editing outcomes (DNA repair pathway choice matters for knock-in efficiency).
On the peptide side, MOTS-c, a mitochondrial-derived peptide, activates some of the same AMPK and metabolic pathways that NAD+ precursors reach indirectly. Some longevity protocols pair NAD+ precursors with peptides under the hypothesis that they hit the same mitochondrial axis through complementary entry points — a reasonable-sounding stack that lacks head-to-head trial data. For broader orientation, our peptides for longevity beginners guide is a good starting point.
Gene editing is also being explored to directly manipulate NAD+ metabolism — for instance, upregulating NAMPT (the rate-limiting salvage enzyme) in specific tissues, or knocking down CD38, a major NAD+ consumer whose expression rises with age. These remain preclinical but illustrate how the field is moving beyond "just take a precursor."
Limitations and What We Don't Know
- Blood NAD+ rises do not automatically mean tissue NAD+ rises in the organs that matter.
- Downstream functional effects have been mostly modest and frequently null on prespecified primary endpoints.
- No lifespan or mortality data exist in humans.
- Dose, formulation, and timing are empirical. The 250–1000 mg/day range is convention, not evidence.
- Cost-per-benefit is poor relative to the evidence base — NMN and NR supplements are not cheap.
- Possible risks from sustained very high doses — methylation depletion, effects on circulating nicotinamide, and theoretical sirtuin-substrate competition at high NAM concentrations.
FAQ
Do NMN and NR actually raise NAD+?
Yes, in blood. Whether they raise it meaningfully in heart, brain, or skeletal muscle in older humans is less certain, with limited tissue biopsy data.
Is NMN or NR better?
The evidence base is slightly larger for NR, but both raise NAD+. No head-to-head trial has established clinical superiority.
Is NMN still legal as a supplement?
The regulatory status has been in flux since the FDA's 2022 ruling. NMN remains widely available but its legal footing is contested and may change.
Did David Sinclair invent NMN?
No. Sinclair's lab did seminal work on sirtuins and has published extensively on NMN in mice. He popularized it but did not discover it.
Do NAD+ precursors extend lifespan?
No human study has tested or shown lifespan extension. Rodent studies are mixed.
Is IV NAD+ more effective than oral precursors?
Popular in clinics, but there's limited evidence that IV NAD+ cleanly enters cells; much may be metabolized to nicotinamide at the membrane. The evidence base is thin.
